Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Non-Current Debt of $15.0 million for Q1 2026, down 66.64% year-over-year from $44.9 million in Q1 2025, and down 71.33% quarter-over-quarter from $52.3 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Non-Current Debt history runs 8 years deep, the most recent figure standing at $15.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 66.64% year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $15.0 million (down 66.64% YoY), while the FY2025 annual figure was $52.3 million, down 12.38% from the prior year.
- Non-Current Debt for Q1 2026 stood at $15.0 million, down from $52.3 million in the prior quarter.
- The five-year high for Non-Current Debt was $59.8 million in Q3 2024, with the low at $15.0 million in Q1 2026.
- The 5-year median for Non-Current Debt is $44.9 million (2025), against an average of $45.5 million.
- The sharpest annual moves came in 2023 and 2026: Non-Current Debt soared 99.68% in 2023, then slumped 66.64% in 2026.
- Rigel Pharmaceuticals' Non-Current Debt stood at $39.4 million in 2022, then soared by 32.76% to $52.4 million in 2023, then gained by 13.95% to $59.7 million in 2024, then dropped by 12.38% to $52.3 million in 2025, then slumped by 71.33% to $15.0 million in 2026.
- Business Quant data shows RIGL's Non-Current Debt at $15.0 million in Q1 2026, $52.3 million in Q4 2025, and $30.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 39.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.24 Mn |
| Mar 31, 2026 | 14.99 Mn |
| Dec 31, 2025 | 52.29 Mn |
| Sep 30, 2025 | 29.97 Mn |
| Jun 30, 2025 | 37.45 Mn |
| Mar 31, 2025 | 44.93 Mn |
| Dec 31, 2024 | 59.68 Mn |
| Sep 30, 2024 | 59.76 Mn |
| Jun 30, 2024 | 59.69 Mn |
| Mar 31, 2024 | 44.91 Mn |
| Dec 31, 2023 | 52.37 Mn |
| Sep 30, 2023 | 59.66 Mn |
| Jun 30, 2023 | 59.57 Mn |
| Mar 31, 2023 | 59.48 Mn |
| Dec 31, 2022 | 39.45 Mn |
| Sep 30, 2022 | 39.47 Mn |
| Jun 30, 2022 | 29.84 Mn |
| Mar 31, 2022 | 29.85 Mn |
| Dec 31, 2021 | 19.91 Mn |
| Sep 30, 2021 | 19.89 Mn |